TELA Bio misses Q2 revenue estimates
Overview
TELA Bio Q2 revenue rises 26% yr/yr but misses analyst expectations, per LSEG data
Net loss for Q2 narrows to $9.92 mln from $12.6 mln a year earlier
Co reiterates 2025 revenue growth guidance of 23% to 27% yr/yr
Outlook
Company reiterates 2025 revenue guidance of $85 mln to $88 mln
TELA Bio projects 23% to 27% revenue growth for 2025
Company focuses on enhanced territory management for growth
TELA Bio expands European market presence with new product launch
Result Drivers
PRODUCT DEMAND - Increased demand for OviTex and OviTex PRS products drove revenue growth, per CEO Antony Koblish
NEW CUSTOMERS - Revenue growth attributed to new customer acquisitions and international sales expansion
PRODUCT MIX - Decrease in average selling prices due to shift towards smaller-sized units
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Miss | $20.20 mln | $20.70 mln (5 Analysts) |
Q2 Net Income |
| -$9.92 mln |
|
Q2 Basic EPS |
| -$0.22 |
|
Q2 Gross Profit |
| $14.10 mln |
|
Q2 Income From Operations |
| -$9.08 mln |
|
Q2 Operating Expenses |
| $23.19 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for TELA Bio Inc is $6.00, about 71.3% above its August 8 closing price of $1.72
Press Release: ID:nGNXbs7zt8
